Clinical Trials on Recurrent High Grade B-Cell Lymphoma

Total 4173 results

National Cancer Institute (NCI)

Completed

Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Immunoblastic Large Cell Lymphoma | Peripheral T-cell Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Hepatosplenic T-cell Lymphoma | Recurrent Adult T-cell Leukemia/Lymphoma | Recurrent Cutaneous T-cell...

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

Waldenstrom Macroglobulinemia | Refractory Plasma Cell Myeloma | Recurrent Adult Hodgkin Lymphoma | Recurrent Adult Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Refractory Non-Hodgkin Lymphoma | Recurrent Plasma Cell Myeloma | Plasma Cell Leukemia and other conditions

United States
University of California, San Francisco
Novartis Pharmaceuticals; Pediatric Brain Tumor Foundation; The Lilabean Foundation...

Recruiting

Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)

High Grade Glioma | Low-grade Glioma | Recurrent World Health Organization (WHO) Grade II Glioma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Recurrent Diffuse Large B-Cell Lymphoma | CD20 Positive | T-Cell Non-Hodgkin Lymphoma

United States
University Hospital Southampton NHS Foundation...

Completed

Immune Responses to COVID-19 Vaccination in Lymphoma Patients (PROSECO)

Follicular Lymphoma | Burkitt Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Lymphoplasmacytic Lymphoma | Peripheral T-cell Lymphoma | Diffuse Large B Cell Lymphoma | Classical Hodgkin Lymphoma | Small Lymphocytic Lymphoma | High-grade B-cell Lymphoma | Nodular Lymphocyte... and other conditions

United Kingdom
University of Chicago
National Cancer Institute (NCI)

Active, not recruiting

Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Splenic Marginal Zone Lymphoma | Waldenström Macroglobulinemia | Cutaneous B-cell Non-Hodgkin Lymphoma | Intraocular Lymphoma | Small Intestine Lymphoma | Testicular Lymphoma | B-cell... and other conditions

United States
Martin, Paul
National Cancer Institute (NCI)

Completed

Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer

Primary Myelofibrosis | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma and other conditions

United States
National Cancer Institute (NCI)

Terminated

Interferon Alfa Plus Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma

United States
Emory University
Novartis

Terminated

Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma

United States
SymBio Pharmaceuticals

Completed

Phase III Study of SyB L-0501 in Combination With Rituximab to Treat Recurrent/Relapsed Diffuse Large B-Cell Lymphoma

Assess the Efficacy and Safety of SyB L-0501 in Combination With Rituximab in Patients With Recurrent or Relapsed DLBCL

Japan
Fred Hutchinson Cancer Center
AstraZeneca

Recruiting

Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma

United States
Fred Hutchinson Cancer Research Center/University...
National Cancer Institute (NCI)

Completed

Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications

Depression | Fatigue | Primary Myelofibrosis | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone... and other conditions

United States
National Cancer Institute (NCI)

Completed

Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Recurrent Adult Lymphoblastic Lymphoma | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Lymphoblastic Leukemia | B-cell Adult Acute Lymphoblastic Leukemia | B-cell Childhood Acute Lymphoblastic Leukemia | T-cell Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood... and other conditions

United States, Canada, Australia, Puerto Rico
University of Rochester

Terminated

A Phase II Study of Doxycycline in Relapsed NHL

Lymphoma, Follicular | Waldenstrom Macroglobulinemia | T-Cell Lymphoma | Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma | Adult Diffuse Large B-Cell Lymphoma | Mantle Cell Lymphoma Recurrent | Marginal Zone B-Cell Lymphoma | Malignant Lymphoma - Lymphoplasmacytic

United States
Seagen Inc.

Terminated

A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma | Diffuse Large B-cell Lymphoma | DLBCL | Grade 3 Follicular Lymphoma

United States
Steven E. Coutre

Completed

Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL

Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma

United States
National Cancer Institute (NCI)

Terminated

Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia

Unspecified Childhood Solid Tumor, Protocol Specific | Peripheral T-cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Childhood Chronic Myelogenous Leukemia | Cutaneous B-cell Non-Hodgkin Lymphoma | Hepatosplenic T-cell Lymphoma | Intraocular Lymphoma | Recurrent Childhood Acute Lymphoblastic... and other conditions

United States, Canada
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer

Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma | Recurrent Adult Lymphoblastic... and other conditions

United States, Germany, Denmark
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); The Wayne D. Kuni and Joan E. Kuni Foundation

Completed

Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer

Diffuse Large B-Cell Lymphoma | Acute Myeloid Leukemia | Refractory Hodgkin Lymphoma | Previously Treated Myelodysplastic Syndrome | Recurrent Mantle Cell Lymphoma | Waldenstrom Macroglobulinemia | Acute Lymphoblastic Leukemia | Refractory Plasma Cell Myeloma | Recurrent Small Lymphocytic Lymphoma | Refractory... and other conditions

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute...

Completed

Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant

Clear Cell Renal Cell Carcinoma | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Juvenile Myelomonocytic Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent... and other conditions

United States, Germany, Italy
Huazhong University of Science and Technology
Shanghai IASO Biotechnology Co., Ltd

Not yet recruiting

Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies

Chronic Lymphocytic Leukemia (CLL) | Peripheral T-cell Lymphomas (PTCL) | CD5+ Relapsed/Refractory Hematopoietic Malignancies | Mantle Cell Lymphoma (MCL) | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL)
Fred Hutchinson Cancer Center

Completed

Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

Primary Myelofibrosis | Essential Thrombocythemia | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Juvenile Myelomonocytic Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated... and other conditions

United States
CTI BioPharma

Completed

Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma

Lymphoma, Mixed-Cell, Follicular | Lymphoma, Small Cleaved-Cell, Follicular | Lymphoma, Low-Grade | Lymphoma, Small Lymphocytic

United States
National Cancer Institute (NCI)

Completed

S0108 Bevacizumab in Treating Patients With Non-Hodgkin's Lymphoma

Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Mantle Cell Lymphoma | Anaplastic Large Cell Lymphoma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaborators

Completed

A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Immunoblastic Large Cell Lymphoma and other conditions

United States
New York Medical College
Roswell Park Cancer Institute

Recruiting

Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL (O-ICE)

Diffuse Large B-Cell Lymphoma | Burkitt Lymphoma | Non-Hodgkin Lymphoma | Primary Mediastinal B-cell Lymphoma | CD20+ Lymphoblastic Lymphoma | Follicular Lymphoma, Grade III

United States
Roswell Park Cancer Institute

Completed

Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Primary Myelofibrosis | Polycythemia Vera | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Juvenile Myelomonocytic Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma and other conditions

United States
Case Comprehensive Cancer Center

Completed

Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Juvenile Myelomonocytic Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type | Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type

United States, Saudi Arabia
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell... and other conditions

United States, Italy
Herlev Hospital
Odense University Hospital; Zealand University Hospital; Aarhus University Hospital and other collaborators

Completed

The Use of Biomarkers to Predict CNS Involvement in Diffuse Large B-Cell Lymphoma: a Danish Nationwide Registry Study (COO-CNS)

Diffuse Large B-cell Lymphoma Recurrent | Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma Cell of Origin
Shanghai YingLi Pharmaceutical Co. Ltd.

Unknown

A Phase I Study of YY-20394 in Patients With B Cell Hematologic Malignancies

B-cell Chronic Lymphocytic Leukemia | B-cell Lymphoma Recurrent

China
Beijing Yongtai Ruike Biotechnology Company Ltd

Recruiting

Phase I Clinical Trial of RC19D2 Cell Injection in the Treatment of Diffuse Large B-cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-cell Lymphoma

China
RenJi Hospital

Recruiting

Zanubrutinib+Lenalidomide+R-ICE in Relapsed/Refractory DLBCL

Diffuse Large B-cell Lymphoma Recurrent | Diffuse Large B Cell Lymphoma Refractory

China
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma

United States
Mehrdad Abedi, MD
National Cancer Institute (NCI)

Recruiting

Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma

United States
Emory University
National Cancer Institute (NCI); Novartis; Secura Bio, Inc.

Recruiting

Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma

United States
ADC Therapeutics S.A.

Completed

Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (LOTIS-2)

Diffuse Large B-cell Lymphoma Recurrent | Diffuse Large B-Cell Lymphoma Refractory

United States, United Kingdom, Italy, Switzerland
Fondazione Italiana Linfomi ONLUS
Janssen Pharmaceutica; Janssen-Cilag Ltd.; Centro di Riferimento per l'Epidemiologia...

Completed

Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP. (FIL_VERAL12)

Diffuse Large B-cell Lymphoma Recurrent | Diffuse Large B-cell Lymphoma Refractory

Italy
Fondazione Italiana Linfomi - ETS
Roche Pharma AG

Not yet recruiting

R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma (FIL_POLARDHAP)

Diffuse Large B-cell Lymphoma Recurrent | Diffuse Large B Cell Lymphoma Refractory

Italy
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Tumor-Specific Clonotype, Metabolic Profile, and PET/CT in Predicting Chemotherapy Response in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma

United States
AstraZeneca
CLL Consortium

Completed

AZD6738 First Time in Patient Multiple Ascending Dose Study

B Cell Lymphomas | 11q-deleted Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL), | Prolymphocytic Leukaemia (PLL)

United States
Zhejiang Cancer Hospital

Recruiting

A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCL

Diffuse Large B-cell Lymphoma Recurrent | Diffuse Large B Cell Lymphoma Refractory

China
Singapore General Hospital
Janssen, LP

Recruiting

RICE-ibrutinib in Relapsed DLBCL

Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma Recurrent

Singapore
University of Nebraska
National Cancer Institute (NCI)

Completed

TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma

United States
The First Affiliated Hospital with Nanjing Medical...

Unknown

Lenalidomide, Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone in Relapse and Refractory DLBCL (R2-GOD)

Diffuse Large B-cell Lymphoma Recurrent | Diffuse Large B Cell Lymphoma Refractory

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma

Progressive Disease | Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Refractory Chronic Lymphocytic Leukemia | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Minimal Residual Disease | Recurrent Chronic Lymphocytic Leukemia | CD19 Positive | CD22...

United States
Kite, A Gilead Company

Recruiting

Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma (ZUMA-23)

High-risk Large B-cell Lymphoma (LBCL)

United States, Austria, Spain, Italy, Australia, Germany, Netherlands, Canada, Portugal, United Kingdom, France

Clinical Trials on Recurrent High Grade B-Cell Lymphoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Montenegro

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations